SPY330.06+1.27 0.39%
DIA268.41+1.69 0.63%
IXIC10,941.17+38.37 0.35%

Benchmark Initiates Coverage On Champions Oncology with Speculative Buy Rating, Announces $11 Price Target

Benchmark initiates coverage on Champions Oncology (NASDAQ:CSBR) with a Speculative Buy rating and a $11 price target.

Benzinga · -

Benchmark initiates coverage on Champions Oncology (NASDAQ:CSBR) with a Speculative Buy rating and a $11 price target.